Indaptus Therapeutics, Inc. Deferred Tax Liabilities, Gross
Indaptus Therapeutics, Inc. (INDP) had Deferred Tax Liabilities, Gross of $17.34 thousand as of 2024-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-17
- 2024-12-31: Deferred Tax Liabilities, Gross $17.34K.
- 2023-12-31: Deferred Tax Liabilities, Gross $36.37K.
- 2022-12-31: Deferred Tax Liabilities, Gross $16.71K.
- 2021-12-31: Deferred Tax Liabilities, Gross $35.51K.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2024-12-31 | $17.34K 10-K · filed 2026-03-17 |
| 2023-12-31 | $36.37K 10-K · filed 2025-03-13 |
| 2022-12-31 | $16.71K 10-K · filed 2024-03-13 |
| 2021-12-31 | $35.51K 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |